SAN FRANCISCO--(BUSINESS WIRE)--Girard Gibbs LLP (www.GirardGibbs.com) filed a federal lawsuit against Takeda Pharmaceuticals and Eli Lilly and Company alleging that the companies failed to warn consumers about the increased risk of bladder cancer associated with Actos, a drug used to treat type 2 diabetes. The plaintiff is jointly represented by Girard Gibbs and The Danko Law Firm.
The complaint alleges that Takeda and Lilly failed to adequately warn the public about the serious health risks associated with pioglitazone, sold under the brand name Actos. Specifically, the lawsuit alleges that those who take Actos are at a greater risk of developing bladder cancer.
On June 15, 2011, an FDA safety alert was issued after studies showed an increased risk of bladder cancer with prolonged usage of Actos. After European studies regarding Actos side effects resulted in similar findings, France and Germany restricted the use of Actos.
“Prescription drug manufacturers are required to issue warnings about the possible risks of negative side effects from their products. When a manufacturer decides not to provide full disclosure of the potential risks from a medication, doctors and patients cannot make informed decisions about what drug is right for them, and as a result, people suffer injuries unnecessarily," said A. J. De Bartolomeo, one of the lead attorneys litigating the case.
If you have contracted bladder cancer after taking Actos and would like more information regarding the lawsuit, please contact Girard Gibbs LLP (www.GirardGibbs.com/Actos-Lawyers.asp), The Danko Law Firm (www.DankoLaw.com), or call 866-981-4800.